Biocytogen Pharmaceuticals (beijing) Co., Ltd.

Biocytogen Jiangsu Co., Ltd.

Beijing Biocytogen Co., Ltd

Meiling Zhang

Yang Bai

Yuelei Shen

Rui Huang

Yanan Guo

Jiawei Yao

Chaoshe Guo

Lei Zhao

Xiaofei Zhou

Chengzhang Shang

Jian Ni

The present disclosure relates to the genetically modified non-human animals that have a disruption at the endogenous CD132 gene (e.g., CD132 knockout), and methods of use thereof

Immunodeficient non-human animal

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) LAG3, and methods of use thereof.

Genetically modified non-human animal with human or chimeric LAG3

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric TIGIT (e.g., humanized TIGIT), and methods of use thereof.

Genetically modified non-human animal with human or chimeric TIGIT

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric OX40, and methods of use thereof.

Genetically modified non-human animal with human or chimeric OX40

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD40, and methods of use thereof.

Genetically modified mice expressing humanized CD40

Genetically modified mouse comprising a chimeric TIGIT

Provided are a humanized transgenic non-human animal, especially a rodent, in particular a transgenic mouse containing a human interleukin 17A (IL-17A) gene, a human gene 17RA (IL-17RA) and/or a human TNF-alpha gene, and a preparation method therefor and the use thereof.

Humanized transgenic animal

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD28, and methods of use thereof.

Genetically modified non-human animal with human or chimeric CD28

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) programmed cell death protein 1 (PD-1), and methods of use thereof. In one aspect, the animals have an insertion of a sequence encoding a human or humanized programmed cell death protein 1 (PD-1) at an endogenous PD-1 gene locus. This animal model can express a PD-1 protein containing a functional domain of the human PD-1 protein, and can be used as an animal model for developing therapeutics for human diseases and disorders, and assessing the toxicity and/or the efficacy of these human therapeutics.

Genetically modified non-human animal with human or chimeric PD-1

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric (e.g., humanized) T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and methods of use thereof.

Genetically modified non-human animal with human or chimeric TIM-3

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL15, and methods of use thereof.

Genetically modified non-human animal with human or chimeric IL15

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD137, and methods of use thereof.

Genetically modified non-human animal with human or chimeric CD137

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL4R and/or IL4, and methods of use thereof.

Genetically modified non-human animal with human or chimeric genes

The present disclosure relates to genetically modified non-human animals (e.g., genetically-modified mice) that express a human or chimeric (e.g., humanized) CD27. The present disclosure also relates to methods of generating the genetically-modified animals (e.g., genetically modified mice), and methods of using the genetically modified non-human animals (e.g., genetically modified mice) described herein.

Growing community of inventors

Beijing, China

Meiling Zhang